Comparative analysis of next-generation KRAS inhibitors in patient derived pancreatic cancer organoids (AACRPanCa 2026) - Oct 15, 2026 - Abstract #B074; "The inhibitors Sotorasib and Adagrasib are approved for treatment of KRAS p.G12C-mutant non-small cell lung cancer (NSCLC)...The tested inhibitors included the approved KRAS p.G12C OFF inhibitor Sotorasib, the second generation KRAS p.G12C OFF inhibitors Divarasib (GDC-6036) (phase III) and D3S-001 (phase II), the KRAS p.G12C ON inhibitor Elironrasib (RMC-6291) (phase II), and the tricomplex pan-RAS ON inhibitor Daraxonrasib (RMC-6236)...In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026; 86(18_Suppl_2):Abstract nr B074."
Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • BRAF • KRAS
|
|
Paul G. Winckler; Georg Vladimirov; Lennart Herrlich; Silke Kowar; Silke Hempel; Maria E. Hess; Caleb Hau; Tobias Hundertmark; Tanja Werner; Rhena F U. Klar; Heiko Becker; Dietrich A. Ruess; Andreas Hoffmann; Tilman Brummer; Melanie Börries
|